Details of the Drug Combination

General Information of Drug Combination (ID: DCL80OR)

Drug Combination Name
5-Fluoro-2-deoxycytidine Tetrahydrouridine
Indication
Disease Entry Status REF
Neoplasms Phase 1 [1]
Component Drugs 5-Fluoro-2-deoxycytidine   DMAVFG9 Tetrahydrouridine   DMR5GSB
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of 5-Fluoro-2-deoxycytidine
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 2 [2]
Indication(s) of Tetrahydrouridine
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 2 [3]
Tetrahydrouridine Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Cytidine deaminase (CDA) TTQ12RK CDD_HUMAN Modulator [4]
------------------------------------------------------------------------------------
Tetrahydrouridine Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cytidine deaminase (CDA) OT3HXP6N CDD_HUMAN Decreases Activity [5]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Adult Acute Myeloid Leukemia DCMFHSG N. A. Phase 1 [6]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT00359606) 5-Fluoro-2'-Deoxcyctidine and Tetrahydrouridine to Treat Patients With Advanced Cancer
2 ClinicalTrials.gov (NCT00978250) A Multi-Histology Phase II Study of 5-Fluoro-2-Deoxycytidine With Tetrahydrouridine (FdCyd + THU). U.S. National Institutes of Health.
3 Quantitative determination of the cytidine deaminase inhibitor tetrahydrouridine (THU) in mouse plasma by liquid chromatography/electrospray ionization tandem mass spectrometry. Rapid Commun Mass Spectrom. 2007;21(13):1991-7.
4 Tetrahydrouridine inhibits cell proliferation through cell cycle regulation regardless of cytidine deaminase expression levels. PLoS One. 2012;7(5):e37424.
5 Comparison of in vitro metabolic conversion of capecitabine to 5-FU in rats, mice, monkeys and humans--toxicological implications. J Toxicol Sci. 2011 Aug;36(4):411-22.
6 ClinicalTrials.gov (NCT01041443) 5-Fluoro-2'-Deoxycytidine and Tetrahydrouridine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes